| CReDO Science | Cannabis Drug Development, Research & Education

Leading experts in clinical

cannabis formulation, research,

and education

ABOUT US

CANNABIS SCIENCE. DONE RIGHT.

CReDO Science was founded by the researcher other experts turn to — built to develop optimized, whole-plant botanical drug formulas, lead original peer-reviewed research, and train the clinicians who need to understand it all.

Work With Us

Explore MM411

20+

GW Pharmaceuticals
Clinical Trials

2

Botanical Drugs
Licensed & Active

1st

Human CBG
Clinical Trial

70+

Peer-Reviewed
Publications

44

Lecturer in 44 Countries

Cannabis can do more than the world currently allows it to do. CReDO exists to close the gap between what the science shows is possible and what patients are actually receiving — because suffering people deserve better, and because better is achievable.

OUR PRINCIPALS

The science is rigorous. The people behind it are real.

Ethan Russo, MD

Founder & CEO

Board-certified neurologist and the world’s foremost phytocannabinoid pharmacologist. 16 years at GW Pharmaceuticals. Medical Monitor for Sativex and Epidiolex across 20+ Phase I-III trials. 70+ peer-reviewed publications. When the field has a hard question, it calls Ethan Russo.

Nishi Whiteley, MS

Co-Founder & COO

35 years of international business development. Author of Chronic Relief. Peer-reviewed co-author alongside Dr. Russo. The commercial architect behind every CReDO engagement — IP portfolio, licensing deals, and the operations that make the science commercially viable.

WHAT WE DO

Three ways we advance cannabis medicine.

Drug Development & Formulation

Whole-plant botanical drug formulas for specific indications. Clinical consulting through at least Phase II. For companies serious about the FDA Botanical Drug pathway.

Original Research

First human CBG clinical trial. First genomic study of CHS. Foundational work on the Entourage Effect and Clinical Endocannabinoid Deficiency. Peer-reviewed science.

Professional Education — MM411

The most rigorous cannabinoid science curriculum available. Written and taught by Dr. Ethan Russo. Built for clinicians, PhDs, and cannabis industry professionals.

ACTIVE PROGRAMS

Cannabis drug development is a long game. We're in it.

CReDO has developed and licensed botanical drug formulas currently in active clinical research on two indications across multiple countries — including a whole-plant formula for ALS symptoms advancing toward clinical trials in 2027 on the FDA Botanical Drug pathway across multiple countries, and a whole-plant formula for menopause symptom relief currently in US-based clinical trials. In both cases, we didn't hand off the formula and walk away. We stayed — providing ongoing clinical consulting through the trial process, as we do with every engagement we take on.

FDA Botanical Drug Pathway